These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20850462)

  • 1. Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.
    Riddle LR; Kumar R; Griffin SA; Grundt P; Newman AH; Luedtke RR
    Neuropharmacology; 2011; 60(2-3):284-94. PubMed ID: 20850462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.
    Kumar R; Riddle L; Griffin SA; Grundt P; Newman AH; Luedtke RR
    Neuropharmacology; 2009; 56(6-7):944-55. PubMed ID: 19371585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
    Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
    Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.
    Rangel-Barajas C; Malik M; Mach RH; Luedtke RR
    Neuropharmacology; 2015 Jun; 93():179-90. PubMed ID: 25698528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
    J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
    Cote SR; Chitravanshi VC; Bleickardt C; Sapru HN; Kuzhikandathil EV
    Behav Brain Res; 2014 Apr; 263():46-50. PubMed ID: 24462727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and cellular dopamine D
    Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
    Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 12. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targeting of G protein-coupled receptor heteromers.
    Moreno E; Casajuana-Martin N; Coyle M; Campos BC; Galaj E; Del Torrent CL; Seyedian A; Rea W; Cai NS; Bonifazi A; Florán B; Xi ZX; Guitart X; Casadó V; Newman AH; Bishop C; Pardo L; Ferré S
    Pharmacol Res; 2022 Nov; 185():106476. PubMed ID: 36182040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP; Millan MJ; Brotchie JM
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.
    Mason CW; Hassan HE; Kim KP; Cao J; Eddington ND; Newman AH; Voulalas PJ
    J Pharmacol Exp Ther; 2010 Jun; 333(3):854-64. PubMed ID: 20228156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.
    Martelle JL; Claytor R; Ross JT; Reboussin BA; Newman AH; Nader MA
    J Pharmacol Exp Ther; 2007 May; 321(2):573-82. PubMed ID: 17272677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
    Monville C; Torres EM; Dunnett SB
    Brain Res Bull; 2005 Dec; 68(1-2):16-23. PubMed ID: 16325000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.